HCG Dosing for Fertility Restoration Post-TRT
For men recovering from testosterone replacement therapy who desire fertility, initiate HCG at 500 IU subcutaneously three times weekly (total 1,500 IU/week), and if spermatogenesis does not adequately recover after 3 months, add FSH 75 IU three times weekly. 1
Initial HCG Monotherapy Protocol
Start with HCG alone before adding FSH, as many men will respond to HCG monotherapy:
- Standard starting dose: 500 IU subcutaneously three times weekly (Monday/Wednesday/Friday schedule) 1, 2
- Dosing range: 500-2,500 IU per week total, typically divided into 2-3 administrations 1, 3
- Alternative FDA-approved regimen: 500-1,000 IU three times weekly for hypogonadotropic hypogonadism 3
The 500 IU three times weekly regimen is supported by the strongest evidence, as this dose maintained spermatogenesis in 100% of men on concurrent TRT in a prospective study, with 9 of 26 men achieving pregnancy 2.
Monitoring and Escalation Strategy
Check response at 2-3 months to determine if escalation is needed 1:
- Measure serum testosterone to confirm testicular response
- Obtain semen analysis to assess sperm concentration and motility
- Check LH and FSH levels (should remain suppressed initially, then gradually recover)
If inadequate response after 3 months of HCG monotherapy, escalate to combination therapy:
- Add FSH 75-150 IU subcutaneously three times weekly 1
- Continue HCG at same dose
- Recent evidence supports higher combination dosing: 3,000 IU HCG plus 75 IU FSH three times weekly achieved spermatogenic improvement in 74% of men with prior testosterone use 4
Expected Timeline and Outcomes
Recovery takes substantial time—set realistic expectations:
- Most men (67-90%) eventually recover spermatogenesis, but this requires 6-24 months 1
- Combination HCG/FSH therapy achieves optimal outcomes: approximately 80% develop spermatogenesis and 50% achieve pregnancy rates when treated for 12-24 months 5
- Older age and longer TRT duration predict slower recovery 1
Critical Mechanism and Dosing Rationale
HCG mimics LH and directly stimulates testicular Leydig cells to produce intratesticular testosterone, which is essential for spermatogenesis 1. The dose-response relationship is well-established:
- Very low doses are effective: Even 125 IU every other day (approximately 440 IU/week) significantly increases intratesticular testosterone in men with experimental gonadotropin deficiency 6
- The 500 IU three times weekly dose (1,500 IU/week total) represents a conservative, evidence-based starting point that balances efficacy with minimizing receptor desensitization 1, 2
Common Pitfalls to Avoid
Never use testosterone monotherapy in men desiring fertility—it causes oligospermia or azoospermia in 40% of patients through negative feedback on gonadotropin secretion 1, 2. However, concurrent testosterone therapy during HCG/FSH treatment does NOT impede spermatogenic recovery: 74% of men improved whether they stayed on testosterone or discontinued it 4.
Avoid excessively high HCG doses, as they can cause Leydig cell receptor desensitization 1. The FDA-approved maximum for hypogonadotropic hypogonadism is 1,000 IU three times weekly 3, though some protocols use up to 3,000 IU three times weekly 4.
Gynecomastia is the most common side effect, occurring due to HCG-stimulated aromatase activity increasing estradiol production 5.
Alternative Regimens Based on Clinical Context
For men with complete azoospermia post-TRT:
- Consider starting with the higher combination regimen immediately: 3,000 IU HCG plus 75 IU FSH three times weekly 4
For men with residual spermatogenesis on TRT:
- The lower dose of 500 IU HCG three times weekly may suffice, as this maintained spermatogenesis in men on concurrent TRT 2
For hypogonadotropic hypogonadism (not TRT-related):